Winner of the 2025 National Pharmaceutical Technology Award (Medical Device Category)
[Bronze Award, Medical Device Category: Bio Preventive Medicine Corp. for "DNlite Test"]
Through a non-invasive urine test, DNlite effectively predicts the 5-year risk of renal function decline in diabetic patients, facilitating personalized care and early medical intervention.
The National Pharmaceutical Technology and Research Development Award remains steadfast in its mission of "Pioneering Pharmaceuticals, Soaring Globally." By continuously advancing technological research and development in drugs and medical devices, the Award drives the robust growth and prosperity of the biomedical industry.
Furthermore, it actively supports President Lai's "Healthy Taiwan" policy, embodying the ultimate vision: "Healthy People, a Stronger Nation, and a Taiwan Embraced by the World."
Related News Links:
Related News
【DNlite Patient Education】A Paradigm Shift in Primary Care
Preventing the "Silent Killer" Chronic Kidney Disease? Dr. Hung-Lin Chen: "Early Screening and Early Treatment is Key!"
2026/01/28
Press
BPM Secures CE IVD Mark for DNlite-IVD103
The World's First Innovative Diagnostic Kit for Preventing Rapid Decline in Diabetic Kidney Disease
2020/02/11
Press
Expanding the ASEAN Footprint: BPM Secures Regulatory Approval in Indonesia for DNlite-IVD103
Expanding the ASEAN Footprint: BPM Secures Regulatory Approval in Indonesia for DNlite-IVD103
2024/05/13
Press